|
|
UBE2I |
ubiquitin conjugating enzyme E2 I |
- Meiotic synapsis
- Vitamin D (calciferol) metabolism
- SUMO is transferred from E1 to E2 (UBE2I, UBC9)
- SUMO is transferred from E1 to E2 (UBE2I, UBC9)
- SUMOylation of DNA damage response and repair proteins
- SUMOylation of transcription factors
- SUMOylation of transcription factors
- SUMOylation of ubiquitinylation proteins
- SUMOylation of transcription cofactors
- SUMOylation of transcription cofactors
- SUMOylation of SUMOylation proteins
- SUMOylation of intracellular receptors
- SUMOylation of intracellular receptors
- SUMOylation of chromatin organization proteins
- SUMOylation of chromatin organization proteins
- SUMOylation of RNA binding proteins
- SUMOylation of DNA replication proteins
- SUMOylation of DNA replication proteins
- SUMOylation of DNA methylation proteins
- SUMOylation of DNA methylation proteins
- SUMOylation of immune response proteins
- Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
- Processing of DNA double-strand break ends
- Formation of Incision Complex in GG-NER
- Negative regulation of activity of TFAP2 (AP-2) family transcription factors
- Negative regulation of activity of TFAP2 (AP-2) family transcription factors
- Postmitotic nuclear pore complex (NPC) reformation
- Maturation of nucleoprotein
- Maturation of nucleoprotein
- SARS-CoV-1 targets host intracellular signalling and regulatory pathways
- SUMOylation of nuclear envelope proteins
- PKR-mediated signaling
- Regulation of endogenous retroelements by KRAB-ZFP proteins
- Transcriptional and post-translational regulation of MITF-M expression and activity
|
|
|
|
|
VAMP1 |
vesicle associated membrane protein 1 |
- Toxicity of botulinum toxin type D (botD)
- Toxicity of botulinum toxin type F (botF)
- Toxicity of botulinum toxin type G (botG)
|
|
|
|
|
VAMP2 |
vesicle associated membrane protein 2 |
- Translocation of SLC2A4 (GLUT4) to the plasma membrane
- Serotonin Neurotransmitter Release Cycle
- Norepinephrine Neurotransmitter Release Cycle
- trans-Golgi Network Vesicle Budding
- Glutamate Neurotransmitter Release Cycle
- Dopamine Neurotransmitter Release Cycle
- Acetylcholine Neurotransmitter Release Cycle
- Insulin processing
- Regulation of insulin secretion
- Lysosome Vesicle Biogenesis
- Golgi Associated Vesicle Biogenesis
- Other interleukin signaling
- Toxicity of botulinum toxin type D (botD)
- Toxicity of botulinum toxin type B (botB)
- Toxicity of botulinum toxin type F (botF)
- Toxicity of tetanus toxin (tetX)
- Toxicity of botulinum toxin type G (botG)
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- GABA synthesis, release, reuptake and degradation
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Insertion of tail-anchored proteins into the endoplasmic reticulum membrane
- Sensory processing of sound by inner hair cells of the cochlea
|
|
|
|
|
VAMP3 |
vesicle associated membrane protein 3 |
- ER-Phagosome pathway
- Retrograde transport at the Trans-Golgi-Network
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
- RHOA GTPase cycle
- RHOB GTPase cycle
- RHOC GTPase cycle
- CDC42 GTPase cycle
- RAC1 GTPase cycle
- RAC2 GTPase cycle
- RHOD GTPase cycle
- RHOQ GTPase cycle
- RHOH GTPase cycle
- RHOG GTPase cycle
- RHOJ GTPase cycle
- RAC3 GTPase cycle
- RHOF GTPase cycle
|
|
|
|
|
VAMP4 |
vesicle associated membrane protein 4 |
- Retrograde transport at the Trans-Golgi-Network
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
|
|
|
|
VAMP5 |
vesicle associated membrane protein 5 |
|
|
|
|
|
VSTM1 |
V-set and transmembrane domain containing 1 |
|
|
|
|
|
WFDC2 |
WAP four-disulfide core domain 2 |
- Formation of the nephric duct
|
|
|
|
|
YIPF6 |
Yip1 domain family member 6 |
- Golgi Associated Vesicle Biogenesis
|
|
|
|
|
ZDHHC15 |
zDHHC palmitoyltransferase 15 |
|
|
- Syndromic X-linked mental retardation with epilepsy or seizures, including: West syndrome (WS); Partington syndrome (PRTS); Proud syndrome (ACCAG); XMR and epilepsy (XMRE); MRXHF1; XMR OPHN1-related (MRXSO) ; XELBD; XMR, Christianson type (MRXSC); Creatine deficiency syndrome (XL-CDS); Renpenning syndrome (RENS1); Epilepsy and mental retardation limited to females (EFMR); Periventricular nodular heterotopia (PVNH); Hydrocephalus (XLH); XMR, JARID1C related (MRXSJ); Boerjeson-Forssman syndrome (BFLS); CK syndrome (CKS)
|